Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, and Chronic Lymphocytic Leukemia Research.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Is Myelodysplasia a Consequence of Normal Aging?
CPX‐351 (Vyxeos<sup>®</sup>) can cause severe rash in acute myeloid leukemia—A case report
CPX-351 (Vyxeos<sup>®</sup>) can cause severe rash in acute myeloid leukemia-A case report.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Guideline-based indicators for adult patients with myelodysplastic syndromes.
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.
Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
Time-dependent changes in mortality and transformation risk in MDS
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes